Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC LTD Mar-18 |
ADCOCK INGRAM Jun-14 |
ALEMBIC LTD/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 365 | - | |
Low | Rs | 34 | 264 | - | |
Sales per share (Unadj.) | Rs | 4.7 | 108.7 | - | |
Earnings per share (Unadj.) | Rs | 6.1 | -27.4 | - | |
Cash flow per share (Unadj.) | Rs | 6.2 | -22.7 | - | |
Dividends per share (Unadj.) | Rs | 0.20 | 0 | - | |
Dividend yield (eoy) | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 40.7 | 85.3 | - | |
Shares outstanding (eoy) | m | 267.03 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 11.3 | 2.9 | 389.3% | |
Avg P/E ratio | x | 8.7 | -11.5 | -75.6% | |
P/CF ratio (eoy) | x | 8.5 | -13.9 | -61.2% | |
Price / Book Value ratio | x | 1.3 | 3.7 | 35.3% | |
Dividend payout | % | 3.3 | 0 | - | |
Avg Mkt Cap | Rs m | 14,139 | 53,081 | 26.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 207 | 3,331 | 6.2% | |
Avg. sales/employee | Rs Th | NM | 4,273.4 | - | |
Avg. wages/employee | Rs Th | NM | 776.0 | - | |
Avg. net profit/employee | Rs Th | NM | -1,076.8 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 18,346 | 6.8% | |
Other income | Rs m | 370 | 128 | 288.2% | |
Total revenues | Rs m | 1,625 | 18,474 | 8.8% | |
Gross profit | Rs m | 111 | -3,179 | -3.5% | |
Depreciation | Rs m | 38 | 792 | 4.8% | |
Interest | Rs m | 2 | 497 | 0.3% | |
Profit before tax | Rs m | 442 | -4,339 | -10.2% | |
Minority Interest | Rs m | 0 | -12 | 0.0% | |
Prior Period Items | Rs m | 1,212 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | 271 | 8.8% | |
Profit after tax | Rs m | 1,630 | -4,623 | -35.3% | |
Gross profit margin | % | 8.9 | -17.3 | -51.1% | |
Effective tax rate | % | 5.4 | -6.2 | -86.8% | |
Net profit margin | % | 129.8 | -25.2 | -515.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 13,437 | 13.9% | |
Current liabilities | Rs m | 591 | 7,560 | 7.8% | |
Net working cap to sales | % | 101.6 | 32.0 | 317.3% | |
Current ratio | x | 3.2 | 1.8 | 177.7% | |
Inventory Days | Days | 94 | 111 | 85.0% | |
Debtors Days | Days | 74 | 124 | 59.3% | |
Net fixed assets | Rs m | 1,791 | 7,832 | 22.9% | |
Share capital | Rs m | 534 | 85 | 627.1% | |
Net worth | Rs m | 10,858 | 14,399 | 75.4% | |
Long term debt | Rs m | 41 | 5,060 | 0.8% | |
Total assets | Rs m | 11,591 | 27,201 | 42.6% | |
Interest coverage | x | 260.9 | -7.7 | -3,374.0% | |
Debt to equity ratio | x | 0 | 0.4 | 1.1% | |
Sales to assets ratio | x | 0.1 | 0.7 | 16.1% | |
Return on assets | % | 14.1 | -15.2 | -92.8% | |
Return on equity | % | 15.0 | -32.1 | -46.8% | |
Return on capital | % | 15.2 | -19.8 | -76.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 1,566 | 15.1% | |
From Investments | Rs m | -224 | -481 | 46.6% | |
From Financial Activity | Rs m | -27 | 4,592 | -0.6% | |
Net Cashflow | Rs m | -15 | 5,678 | -0.3% |
Compare ALEMBIC LTD With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ALEMBIC LTD With: SANOFI INDIA DISHMAN PHARMA ALKEM LABORATORIES FULFORD INDIA PIRAMAL ENTERPRISES
| |
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Should you subscribe to the IPO of Shalby Ltd?
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsTanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
This is the trick to following super investors and not losing money.
While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More
| |